These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1396 related items for PubMed ID: 18349297
1. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study. Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ. Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297 [Abstract] [Full Text] [Related]
6. Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Mulholland HG, Cantwell MM, Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, McGuigan J, Reynolds JV, Comber H, Murray LJ. Cancer Causes Control; 2009 Apr; 20(3):279-88. PubMed ID: 18839322 [Abstract] [Full Text] [Related]
7. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Olliver JR, Hardie LJ, Gong Y, Dexter S, Chalmers D, Harris KM, Wild CP. Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340 [Abstract] [Full Text] [Related]
8. Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Casson AG, Zheng Z, Evans SC, Veugelers PJ, Porter GA, Guernsey DL. Carcinogenesis; 2005 Sep; 26(9):1536-41. PubMed ID: 15878910 [Abstract] [Full Text] [Related]
9. Prediction of malignant potential in reflux disease: are cytokine polymorphisms important? Gough MD, Ackroyd R, Majeed AW, Bird NC. Am J Gastroenterol; 2005 May; 100(5):1012-8. PubMed ID: 15842572 [Abstract] [Full Text] [Related]
10. Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer. Brewster AM, Jorgensen TJ, Ruczinski I, Huang HY, Hoffman S, Thuita L, Newschaffer C, Lunn RM, Bell D, Helzlsouer KJ. Breast Cancer Res Treat; 2006 Jan; 95(1):73-80. PubMed ID: 16319991 [Abstract] [Full Text] [Related]
11. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, Comber H, McGuigan J, Reynolds JV, Murray LJ. Cancer Res; 2006 May 01; 66(9):4975-82. PubMed ID: 16651456 [Abstract] [Full Text] [Related]
12. A population-based study of the Arg399Gln polymorphism in X-ray repair cross- complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Duell EJ, Holly EA, Bracci PM, Wiencke JK, Kelsey KT. Cancer Res; 2002 Aug 15; 62(16):4630-6. PubMed ID: 12183419 [Abstract] [Full Text] [Related]
13. hOGG1 Ser326Cys and XRCC1 Arg399Gln polymorphisms associated with chronic obstructive pulmonary disease. Yang SF, Xu YJ, Xie JG, Zhang ZX. Chin Med J (Engl); 2009 Apr 20; 122(8):960-6. PubMed ID: 19493423 [Abstract] [Full Text] [Related]
14. A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma. Murphy SJ, Hughes AE, Patterson CC, Anderson LA, Watson RG, Johnston BT, Comber H, McGuigan J, Reynolds JV, Murray LJ. Carcinogenesis; 2007 Jun 20; 28(6):1323-8. PubMed ID: 17277236 [Abstract] [Full Text] [Related]
15. Barrett's esophagus and medications that relax the lower esophageal sphincter. Corley DA, Levin TR, Habel LA, Buffler PA. Am J Gastroenterol; 2006 May 20; 101(5):937-44. PubMed ID: 16573773 [Abstract] [Full Text] [Related]
16. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. Menke V, Pot RG, Moons LM, van Zoest KP, Hansen B, van Dekken H, Siersema PD, Kusters JG, Kuipers EJ. J Hum Genet; 2012 Jan 20; 57(1):26-32. PubMed ID: 22129558 [Abstract] [Full Text] [Related]
17. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV. Am J Gastroenterol; 2005 Jun 20; 100(6):1257-64. PubMed ID: 15929754 [Abstract] [Full Text] [Related]
18. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, Vallböhmer D, Schäfer H, Danenberg KD, Danenberg PV, Selaru FM, Baldus SE, Hölscher AH, Meltzer SJ, Schneider PM. Cancer Epidemiol Biomarkers Prev; 2005 Sep 20; 14(9):2113-7. PubMed ID: 16172218 [Abstract] [Full Text] [Related]
19. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. Abe Y, Ohara S, Koike T, Sekine H, Iijima K, Kawamura M, Imatani A, Kato K, Shimosegawa T. Am J Gastroenterol; 2004 Jul 20; 99(7):1213-21. PubMed ID: 15233656 [Abstract] [Full Text] [Related]
20. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K, Velghe A, Van Meerbeeck J, Thierens H. Mutat Res; 2007 Jul 28; 631(2):101-10. PubMed ID: 17531525 [Abstract] [Full Text] [Related] Page: [Next] [New Search]